The quality and safety of blood and blood products is a major concern to the health community. The goal is to prevent, as completely as possible, the transmission of infectious or potentially dangerous particles. In CHI's 10th conference top notch experts discuss how this can be achieved in presenting answers to the following questions:
What are the newest and most precise
Which agents need to be screened for?
Which new pathogens are a potential
threat to humans?
How early can pathogens be detected?
Which donors are being excluded/included?
Existing and Emerging Pathogens
Detecting and Screening Technologies
Inactivation Strategies and Quality
A Forum on TSE Diagnostic Blood Tests
Dr. Thomas R. Kreil, Baxter Bioscience
Dr. Subhash Dhawan, FDA
Dr. Thomas R. Kreil, Director of Global Pathogen Safety, Baxter Bioscience, Austria
Dr. Matthew J. Kuehnert, M.D., CDR, U.S. Public Health Service, Assistant Director for Blood Safety, Centers for Disease Control and
The Definitive American TSE Meeting
March 7-8, 2006 MD
Protein Folding Disorders
March 9, 2006